BERIPLEX

This brand name is authorized in Austria, Brazil, Canada, Croatia, Cyprus, Hong Kong SAR China, Ireland, Malta, Netherlands, New Zealand, Poland, Romania, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug BERIPLEX contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII 8FB1K07F16 - PROTHROMBIN
 
Read more about Thrombin
2
UNII 4156XVB4QD - COAGULATION FACTOR VII HUMAN
 
Read more about Coagulation factor VII
3
UNII 6U90Y1795T - COAGULATION FACTOR IX HUMAN
 

Factor IX is a single chain glycoprotein with a molecular mass of about 68,000 Dalton. It is a vitamin-K dependent coagulation factor and it is synthesised in the liver. Factor IX is activated by factor XIa in the intrinsic coagulation pathway and by the factor VII/tissue factor complex in the extrinsic pathway. Activated factor IX, in combination with activated factor VIII, activates factor X.

 
Read more about Coagulation factor IX
4
UNII 0P94UQE6SY - COAGULATION FACTOR X HUMAN
 

Coagulation factor X is derived from human plasma and used as a replacement for the naturally existing coagulation factor X in patients with hereditary factor X deficiency.

 
Read more about Coagulation factor X
5
UNII 3Z6S89TXPW - PROTEIN C
 

Protein C is a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S. Protein C exerts its effect by the inactivation of the activated forms of factors V and VIII which leads to a decrease in thrombin formation. Protein C has also been shown to have profibrinolytic effects.

 
Read more about Protein C
6
UNII 90J3F6N5FN - PROTEIN S HUMAN
 
Read more about Protein S

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
B02BD01 Coagulation factor IX, II, VII and X in combination B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BD Blood coagulation factors
Discover more medicines within B02BD01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
BR Câmara de Regulação do Mercado de Medicamentos 502600704155416, 502618080008107
CA Health Products and Food Branch 02359251, 02410826
ES Centro de información online de medicamentos de la AEMPS 69890, 76961
GB Medicines & Healthcare Products Regulatory Agency 109230, 109234, 223222
HK Department of Health Drug Office 58741
HR Agencija za lijekove i medicinske proizvode HR-H-899027590
MT Medicines Authority MA665/00301, MA665/00302
NL Z-Index G-Standaard 15353397, 15353400
NL Z-Index G-Standaard, PRK 71927, 71935
NZ Medicines and Medical Devices Safety Authority 20416, 20498, 20499
PL Rejestru Produktów Leczniczych 100116573, 100204018, 100204024
RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale W62579001, W62580001
TN Direction de la Pharmacie et du Médicament 8143081H
TR İlaç ve Tıbbi Cihaz Kurumu 8681624980187, 8681624980194

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.